UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41242 ZIMVIE INC. Westminster, CO 80021 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification N ...

Page 2 *Assumes year-over-year Dental Net Sales growth of flat to low-single-digits, and year-over year Spine Net Sales to decline in the high single digits to low double digits, inclusive of an approximate 3.0 percentage point impact to our Spine business from our decision to exit the China market. [1] This is a forward-looking non-GAAP financial measure. See "Forward-Looking Non-GAAP Financial Measures" in the Appendix for further information. [2] Excludes one-time share-based compensation expense due to ...

ZimVie Inc. (NASDAQ:ZIMV) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Rich Heppenstall - Chief Financial Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Matt Miksic - Barclays Operator Good afternoon, and welcome to ZimVie’s Second Quarter 2023 Earnings Conference Call. Currently, all participants are in listen-only mode. We will be facilita ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact Name of Registrant as Specified in its Charter) Delaware 87-2007795 ( State or other jurisdiction of incorporation or organization) 10225 Westmoor Driv ...

Financial Data and Key Metrics Changes - Total third-party net sales for Q1 2023 were $225.1 million, a decrease of 4.1% on a reported basis and a decrease of 2.9% in constant currency [9] - Adjusted gross profit was $156 million, compared to $149.3 million in the prior-year period, with an adjusted gross margin of 69.3%, an increase of 570 basis points from 63.6% in Q1 2022 [28] - Adjusted EBITDA in Q1 2023 was $32.1 million or 14.3% of third-party net sales, reflecting a decline of 10 basis points from 14.4% in the prior-year period [29] Business Line Data and Key Metrics Changes - Global dental third-party net sales were $120.2 million, effectively flat on a reported basis and increased 1.8% in constant currency compared to the prior-year period [27] - In the U.S., dental third-party net sales of $69.9 million increased by 2.3%, while outside the U.S., sales of $50.3 million decreased by 3.8% on a reported basis but increased 1.1% in constant currency [73] - First-quarter global spine third-party net sales were $104.9 million, an 8.1% decrease on a reported basis and a 7.8% decrease in constant currency compared to the prior-year period [73] Market Data and Key Metrics Changes - The impact of exiting the China market is estimated to be $2.4 million or 2.4 percentage points of consolidated spine growth [10] - The spine business continues to face competition, affecting sales performance [73] Company Strategy and Development Direction - The company is focused on commercial execution and innovation, with plans to position the business for growth into 2024 and beyond [4] - Recent product launches in the dental segment, including the RealGUIDE software and new bone graft solutions, aim to enhance efficiency and expand market presence [5][24] - The partnership with Brainlab is expected to enhance workflow and accuracy in spinal surgeries, indicating a strategic focus on integrating technology with product offerings [7] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the operational improvements and commercial focus, indicating a belief that the company is on a path to stabilization [39] - The company revised its expected 2023 net sales to a range of $835 million to $860 million, reflecting a positive outlook despite challenges [30] - Management acknowledged the need for prudence due to external factors impacting the business [49] Other Important Information - The company prepaid $10.5 million of debt in Q1 2023, indicating a commitment to reducing leverage [12] - The dental business is well-positioned to grow and generate cash flow, supported by recent product innovations and customer engagement [6] Q&A Session All Questions and Answers Question: What does the sales cadence look like for dental and spine for the rest of the year? - Management indicated that while Q1 was strong, they are cautious about predicting sales for the rest of the year due to various factors impacting the business [17] Question: How does SG&A expense relate to revenue and what are the expectations moving forward? - Management noted that SG&A expenses are expected to remain higher than the prior year for Q2 and Q3 2023, but they anticipate improvements in gross margin to offset some of these costs [11][36] Question: Can you provide insights on the dental market performance relative to competitors? - Management stated that they believe they are performing at or better than the market for premium dental implants, attributing success to their commercial team's efforts and product innovations [40][59]

| --- | --- | |--------------------------------------------------|-------| | | | | Supplemental Financial Information May 3, 2023 | | Disclaimer FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies or prospects. We generally use the words " ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for Q1 2023 and 2022, showing a net loss of $30.0 million for the current quarter Financial Highlights | Metric | Three Months Ended March 31, 2023 ($M) | Three Months Ended March 31, 2022 ($M) | | :--- | :--- | :--- | | **Total Net Sales** | $225.4 | $235.6 | | **Operating Loss** | ($16.1) | ($32.6) | | **Net Loss** | ($30.0) | ($25.7) | | **Net Loss Per Share - Basic & Diluted** | ($1.14) | ($0.98) | Balance Sheet Highlights | Metric | March 31, 2023 ($M) | December 31, 2022 ($M) | | :--- | :--- | :--- | | **Total Assets** | $1,588.1 | $1,642.1 | | **Total Liabilities** | $844.5 | $883.5 | | **Total Stockholders' Equity** | $743.6 | $758.6 | Cash Flow Highlights | Metric | Three Months Ended March 31, 2023 ($M) | Three Months Ended March 31, 2022 ($M) | | :--- | :--- | :--- | | **Net cash used in operating activities** | ($7.2) | ($9.9) | | **Net cash used in investing activities** | ($5.8) | ($8.1) | | **Net cash (used in) provided by financing activities** | ($10.9) | $22.2 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Detailed notes support financial statements, covering company background, segment data, debt, and restructuring initiatives - As of February 1, 2023, former parent company Zimmer Biomet had sold all of its **19.7% ownership** in ZimVie and is no longer considered a related party[23](index=23&type=chunk)[71](index=71&type=chunk)[74](index=74&type=chunk) Segment Performance | Segment | Net Sales (Q1 2023, $M) | Net Sales (Q1 2022, $M) | Operating Profit (Q1 2023, $M) | Operating Profit (Q1 2022, $M) | | :--- | :--- | :--- | :--- | :--- | | **Dental** | $120.2 | $120.6 | $23.0 | $25.7 | | **Spine** | $104.9 | $114.1 | $10.2 | $5.1 | - In June 2022, the company initiated a restructuring plan, which included exiting its spine products activities in China. In April 2023, additional restructuring was initiated to reduce the global cost structure, with anticipated total charges of **$15-16 million**[85](index=85&type=chunk)[87](index=87&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2023 performance, highlighting a **4.3% decrease in total net sales** and narrowed operating loss [Results of Operations](index=20&type=section&id=Results%20of%20Operations) Total net sales decreased by **4.3% to $225.4 million** in Q1 2023, with improved operating loss due to reduced cost of products sold Net Sales by Product Category | Product Category | Q1 2023 Net Sales ($M) | % Change vs Q1 2022 (%) | Volume/Mix Change (%) | Price Change (%) | Foreign Exchange Impact (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | **Dental** | $120.2 | (0.3)% | 2.0% | (0.2)% | (2.1)% | | **Spine** | $104.9 | (8.1)% | (6.9)% | (0.9)% | (0.3)% | | **Total Third Party** | $225.1 | (4.1)% | (2.3)% | (0.6)% | (1.2)% | - The decrease in cost of products sold as a percentage of net sales was primarily due to a reduction in inventory charges in the spine product category and non-recurrence of certain share-based compensation expenses from the prior year[107](index=107&type=chunk) - SG&A expenses decreased due to lower variable selling expenses, cost containment measures, and a **$7.0 million decrease** in share-based compensation that was recorded in the prior year period related to the spin-off[110](index=110&type=chunk) [Restructuring and Other Cost Reduction Initiatives](index=19&type=section&id=Restructuring%20and%20Other%20Cost%20Reduction%20Initiatives) Restructuring includes exiting China spine market and a new program to reduce global workforce by **5%**, targeting **$17-20 million** in annualized savings - The company is exiting its spine products activities in China following an unsuccessful bid in the national volume-based procurement (VBP) program in late 2022[96](index=96&type=chunk) - In April 2023, a new restructuring program was initiated with the objective of reducing the global workforce by approximately **5%** and generating **$17-20 million** in annualized net savings by 2024[100](index=100&type=chunk)[101](index=101&type=chunk) [Liquidity and Capital Resources](index=22&type=section&id=Liquidity%20and%20Capital%20Resources) Cash and cash equivalents decreased to **$66.4 million** as of March 31, 2023, with **$7.2 million** net cash used in operating activities - Cash and cash equivalents decreased to **$66.4 million** as of March 31, 2023, from **$89.6 million** as of December 31, 2022[120](index=120&type=chunk) - Net cash used in operating activities was **$7.2 million** in Q1 2023, compared to **$9.9 million** in Q1 2022[121](index=121&type=chunk) - In Q1 2023, the company used **$10.9 million** in financing activities, which included prepaying debt scheduled for the first half of 2024[123](index=123&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=23&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from foreign currency and interest rates, with a **100 basis point SOFR increase** potentially raising annual pre-tax loss by **$5.3 million** - The company is primarily exposed to foreign currency exchange rate risk with respect to the Euro, Chinese Renminbi, Israeli Shekel, New Zealand Dollar, Japanese Yen, Canadian Dollar, and Swedish Krona[129](index=129&type=chunk) - A hypothetical **100 basis point increase** in the SOFR interest rate on the company's **$525.9 million** of floating rate debt would increase its annual pre-tax loss by approximately **$5.3 million**[131](index=131&type=chunk) - Credit risk is concentrated with public and private hospitals and dental practices, particularly in Europe where healthcare is often government-sponsored, exposing the company indirectly to government budget constraints[133](index=133&type=chunk) [Item 4. Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of March 31, 2023, with no material changes to internal controls - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective as of March 31, 2023[135](index=135&type=chunk) - No changes in internal control over financial reporting occurred during the three months ended March 31, 2023, that have materially affected, or are reasonably likely to materially affect, internal controls[136](index=136&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various legal proceedings, but management does not anticipate a material adverse impact on financial results - The company is subject to various claims and legal proceedings but does not currently expect the outcome of these matters to have a material adverse impact on its financial results[138](index=138&type=chunk) [Item 1A. Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) No material changes have occurred in the risk factors previously disclosed in the company's Annual Report on Form 10-K - There have been no material changes in the risk factors from those discussed in the company's Annual Report on Form 10-K[140](index=140&type=chunk) [Item 6. Exhibits](index=25&type=section&id=Item%206.%20Exhibits) This section indexes exhibits filed with the Form 10-Q, including corporate governance documents and officer certifications - The report includes a list of filed exhibits, such as the Amended and Restated Certificate of Incorporation, Bylaws, and officer certifications pursuant to the Sarbanes-Oxley Act of 2002[141](index=141&type=chunk)

ZimVie Inc. (NASDAQ:ZIMV) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Vafa Jamali - President & Chief Executive Officer Rich Heppenstall - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Operator Good afternoon and welcome to ZimVie's Fourth Quarter and Full Year 2022 Earnings Conference Call. Currently, all participants are in a listen-only mode. We will be facilitating question-and-answer session towards the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41242 ZIMVIE INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organizatio ...

ZimVie Inc. (NASDAQ:ZIMV) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group IR Vafa Jamali - President and CEO Rich Heppenstall - CFO Conference Call Participants Operator Good afternoon, and welcome to ZimVie's Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Marissa Bych from Gilmartin Group Investor Relations for a few ...